[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352767-105":59,"doc-detail-352767-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-molecular-characterization-of-cfdna-as-predictive-and-monitoring-biomarkers-in-advanced-gastric-cancer-receiving-immunotherapy","Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy","","Advanced gastric cancer shows substantial heterogeneity in response to combination immunotherapy, limiting reliable biomarker selection. A cohort of 94 patients received combination immunotherapy and was split into discovery (n=49) and internal validation (n=45) sets, with plasma cfDNA profiled by low-pass and bisulfite sequencing. Responders exhibited longer cfDNA, lower cfDNA tumor fraction, reduced chromosomal instability, and higher global methylation. A baseline DMR at chr20:25849353-25849490 predicted response with improved AUC over PD-L1 CPS and supported on-treatment methylation monitoring.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-molecular-characterization-of-cfdna-as-predictive-and-monitoring-biomarkers-in-advanced-gastric-cancer-receiving-immunotherapy/352767/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-molecular-characterization-of-cfdna-as-predictive-and-monitoring-biomarkers-in-advanced-gastric-cancer-receiving-immunotherapy/352767.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was cfDNA profiled in the discovery and validation sets?","Question",{"text":112,"@type":113},"Plasma cfDNA was collected before and after treatment. The discovery set used low-pass whole-genome sequencing and whole-genome bisulfite sequencing, while the validation set used targeted bisulfite sequencing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cfDNA methylation marker predicted immunotherapy response?",{"text":117,"@type":113},"Baseline methylation of the differentially methylated region at chr20:25849353-25849490 predicted response and improved performance beyond PD-L1 combined positive score (CPS).",{"name":119,"@type":110,"acceptedAnswer":120},"How did cfDNA features differ between responders and non-responders?",{"text":121,"@type":113},"Responders had longer cfDNA, lower cfDNA tumor fraction, reduced chromosomal instability, and higher global methylation compared with non-responders.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352767,1790165540,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Open access Original research  \n Comprehensive molecular  \ncharacterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy  \nJingshuai Fang,1,2,3 Yuhui Yu,2 Yan Sun,2,4 Mengmeng Ji,5,6 Yue Jiang,2 Xiaofeng Chen,7,8 Caiwang Yan,1,2,3 Guangfu Jin  1,2,4  \nTo cite: Fang J, Yu Y, Sun Y, et al. Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy. Journal for ImmunoTherapy of Cancer 2026;14:e013792 . doi:10 . 1136/ jitc-2025-013792  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013792](jitc-2025-013792)) .  \nJF, YY and YS contributed equally.  \nAccepted 01 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Guangfu Jin; [guangfujin@njmu.edu.cn](guangfujin@njmu.edu.cn)  \nProfessor Caiwang Yan; [caiwangyan@njmu.edu.cn](caiwangyan@njmu.edu.cn)  \nABSTRACT  \nBackground Advanced gastric cancer (aGC) exhibits substantial heterogeneity in response to combination immunotherapy. Circulating cell-free DNA (cfDNA) enables non-invasive profiling of tumor dynamics and may provide biomarkers for response prediction.  \nMethods We enrolled 94 patients with aGC undergoing combination immunotherapy and assigned them toa discovery set (n=49) and an internal validation set (n=45) . Plasma cfDNA was collected pre-treatment and post-treatment and profiled by low-pass whole-genome sequencing and whole-genome bisulfite sequencing in the discovery set, with targeted bisulfite sequencing used in the validation set.  \nResults The discovery set included 34 respondersand 15 non-responders, and the validation set included  \n30 responders and 15 non-responders. We found that responders showed longer cfDNA, lower cfDNA tumor fraction (median: 0.06 vs 0 .01, p\u003C0 .001), reduced chromosomal instability (median genomic instability index: 0.026 vs 0 .007, p\u003C0 .001), and higher global methylation (median: 0.715 vs 0 .724, p=0 .007) . Additionally, the differentially methylated region (DMR) at chr20:25849353-25849490 consistently showed higher methylation in responders in both the discovery (adjusted p=0 .006) and validation sets (adjusted p=0 .049) . A predictor based on this DMR outperformed programmed death-ligand 1 (PD-L1) combined positive score (CPS) with area under the curve (AUCs) of 0.79 (discovery: 95% CI 0.65 to 0 .93) and 0.72 (validation: 95% CI 0.54 to 0 .91) . When integrating PD-L1 CPS with this DMR, the AUCs were 0.81 (discovery: 95% CI 0.67 to 0 .95) and  \n0.75 (validation: 95% CI 0.56 to 0 .94), respectively. For on-treatment monitoring, three DMRs increased specifically in responders; among them, increased methylation of chr8:110479193-110480324 and chr8:50891437-50892120 was associated with improved progression-free survival (median: 4.90 vs 11.57 months, p\u003C0 .001; median: 5.20 vs 10.20 months, p=0 .007) . Conclusion Integrated cfDNA profiling captures immunotherapy-associated molecular dynamics in  \naGC. A single pretreatment cfDNA methylation marker (chr20:25849353-25849490) improves response prediction beyond PD-L1 CPS and represents a potential predictive biomarker for combination immunotherapy.  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Currently, programmed death-ligand 1 (PD-L1) combined positive score, tumor mutation burden, and microsatellite instability are regarded as the most reliable predictive biomarkers for response to immunotherapy. However, significant intrapatient heterogeneity and the lack of adequate tumor tissue may limit their effectiveness in clinical practice.\u003Cbr>WHAT THIS STUDY ADDS |\n| ⇒ This study establishes a novel multidimensional circula","cbCaih8MvFaczHkt","https://ap.wps.com/l/cbCaih8MvFaczHkt","pdf",3683591,14,"English","# Background\n# Methods\n## Patient cohorts and cfDNA profiling\n# Results\n## Response-associated cfDNA features\n## Predictive DMR performance\n## On-treatment monitoring markers\n# Conclusion\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"How was cfDNA profiled in the discovery and validation sets?\",\"answer\":\"Plasma cfDNA was collected before and after treatment. The discovery set used low-pass whole-genome sequencing and whole-genome bisulfite sequencing, while the validation set used targeted bisulfite sequencing.\"},{\"question\":\"Which cfDNA methylation marker predicted immunotherapy response?\",\"answer\":\"Baseline methylation of the differentially methylated region at chr20:25849353-25849490 predicted response and improved performance beyond PD-L1 combined positive score (CPS).\"},{\"question\":\"How did cfDNA features differ between responders and non-responders?\",\"answer\":\"Responders had longer cfDNA, lower cfDNA tumor fraction, reduced chromosomal instability, and higher global methylation compared with non-responders.\"}]","Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy | PDF",1790101277,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d8fe91fc2c54379e6c4012dca4d60e5.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a7e761f4ddb8a0f79c62e36f91aabc4.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54b10f29dc8b42703bdb7908765be0a2.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52d42a2b0a6a10ab50d27466cf7d48c6.webp",980,1306]